Armata Pharmaceuticals Inc.

3.3500.00Vol 3.34K1Y Perf -22.27%
Jun 24th, 2022 16:00 DELAYED
BID3.40 ASK5.11
Open3.73 Previous Close3.35
Pre-Market- After-Market-
 - -  - -%
Target Price
7.67 
Analyst Rating
Strong Buy 1.00
Potential %
128.96 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     47.87
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.44 
Earnings Rating
Market Cap120.98M 
Earnings Date
11th Aug 2022
Alpha-0.00 Standard Deviation0.20
Beta1.09 

Today's Price Range

3.353.73

52W Range

2.826.49

5 Year PE Ratio Range

-2.00-0.3000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.46%
1 Month
-20.52%
3 Months
-35.45%
6 Months
-40.81%
1 Year
-22.27%
3 Years
-6.94%
5 Years
-72.18%
10 Years
-99.75%

TickerPriceChg.Chg.%
ARMP3.350.00000.00
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
7.70
7.80
0.37
0.62
-13 216.00
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
-
-2 854.30
-2 712.60
-
-
RevenueValueIndustryS&P 500US Markets
1.17M
0.03
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.20-0.30-50.00
Q04 2021-0.25-0.238.00
Q03 2021-0.26-0.2215.38
Q02 2021-0.25-0.250.00
Q01 2021-0.28-0.273.57
Q04 2020--0.36-
Q03 2020-0.17-0.31-82.35
Q02 2020-0.23-0.26-13.04
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.26
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume3.34K
Shares Outstanding36.11K
Shares Float16.62M
Trades Count74
Dollar Volume11.41K
Avg. Volume8.60K
Avg. Weekly Volume13.08K
Avg. Monthly Volume5.98K
Avg. Quarterly Volume6.75K

Armata Pharmaceuticals Inc. (AMEX: ARMP) stock closed at 3.35 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 3.34K shares and market capitalization of 120.98M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 62 people. Armata Pharmaceuticals Inc. CEO is Todd R. Patrick.

The one-year performance of Armata Pharmaceuticals Inc. stock is -22.27%, while year-to-date (YTD) performance is -38.87%. ARMP stock has a five-year performance of -72.18%. Its 52-week range is between 2.82 and 6.49, which gives ARMP stock a 52-week price range ratio of 14.44%

Armata Pharmaceuticals Inc. currently has a PE ratio of -3.60, a price-to-book (PB) ratio of 2.12, a price-to-sale (PS) ratio of 111.92, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.53%, a ROC of -35.94% and a ROE of -56.45%. The company’s profit margin is -%, its EBITDA margin is -2 712.60%, and its revenue ttm is $1.17 Million , which makes it $0.03 revenue per share.

Of the last four earnings reports from Armata Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. Armata Pharmaceuticals Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Armata Pharmaceuticals Inc. is Strong Buy (1), with a target price of $7.67, which is +128.96% compared to the current price. The earnings rating for Armata Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Armata Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Armata Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.97, ATR14 : 0.41, CCI20 : -109.81, Chaikin Money Flow : -0.12, MACD : -0.29, Money Flow Index : 28.40, ROC : -25.22, RSI : 37.75, STOCH (14,3) : 21.35, STOCH RSI : 0.63, UO : 28.66, Williams %R : -78.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Armata Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. The company is developing and advancing lead clinical phage candidate for Pseudomonas aeruginosa (P. aeruginosa), AP-PA02. It is also focused on developing a phage product candidate for Staphylococcus aureus (S. aureus) for the treatment of S. aureus bacteremia, AP-SA02.

CEO: Todd R. Patrick

Telephone: +1 858 829-0829

Address: 4503 Glencoe Avenue, Marina del Rey 90292, CA, US

Number of employees: 62

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

72%28%

Bearish Bullish

68%32%

TipRanks News for ARMP

News

Stocktwits